Passage Bio, Inc.

NasdaqGS:PASG Voorraadrapport

Marktkapitalisatie: US$38.4m

Passage Bio Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

Passage Bio heeft een totaal eigen vermogen van $72.7M en een totale schuld van $0.0, wat de schuld-eigenvermogensverhouding op 0% brengt. De totale activa en totale passiva bedragen respectievelijk $111.8M en $39.0M.

Belangrijke informatie

0%

Verhouding schuld/eigen vermogen

US$0

Schuld

Rente dekkingsration/a
ContantUS$84.83m
AandelenUS$72.72m
Totaal verplichtingenUS$39.04m
Totaal activaUS$111.75m

Recente financiële gezondheidsupdates

Recent updates

Is Passage Bio (NASDAQ:PASG) In A Good Position To Deliver On Growth Plans?

Sep 24
Is Passage Bio (NASDAQ:PASG) In A Good Position To Deliver On Growth Plans?

Is Passage Bio (NASDAQ:PASG) In A Good Position To Deliver On Growth Plans?

Jun 11
Is Passage Bio (NASDAQ:PASG) In A Good Position To Deliver On Growth Plans?

We're Keeping An Eye On Passage Bio's (NASDAQ:PASG) Cash Burn Rate

Feb 27
We're Keeping An Eye On Passage Bio's (NASDAQ:PASG) Cash Burn Rate

Is Passage Bio (NASDAQ:PASG) In A Good Position To Deliver On Growth Plans?

Nov 13
Is Passage Bio (NASDAQ:PASG) In A Good Position To Deliver On Growth Plans?

We Think Passage Bio (NASDAQ:PASG) Needs To Drive Business Growth Carefully

Jun 23
We Think Passage Bio (NASDAQ:PASG) Needs To Drive Business Growth Carefully

Is Passage Bio (NASDAQ:PASG) In A Good Position To Deliver On Growth Plans?

Nov 13
Is Passage Bio (NASDAQ:PASG) In A Good Position To Deliver On Growth Plans?

Passage appoints William Chou CEO

Oct 10

Passage Bio GAAP EPS of -$0.73 beats by $0.09

Aug 04

We're A Little Worried About Passage Bio's (NASDAQ:PASG) Cash Burn Rate

Jun 03
We're A Little Worried About Passage Bio's (NASDAQ:PASG) Cash Burn Rate

Passage Bio: Worth Keeping An Eye On

Apr 11

Will Passage Bio (NASDAQ:PASG) Spend Its Cash Wisely?

Dec 15
Will Passage Bio (NASDAQ:PASG) Spend Its Cash Wisely?

Passage Bio (NASDAQ:PASG) Is In A Good Position To Deliver On Growth Plans

Aug 19
Passage Bio (NASDAQ:PASG) Is In A Good Position To Deliver On Growth Plans

Passage Bio: Price Reduced, But Without Data, Does Not Look Convincing

Jun 06

Passage Bio partners with InformedDNA to offer counseling, testing for early dementia

May 03

We're Hopeful That Passage Bio (NASDAQ:PASG) Will Use Its Cash Wisely

Mar 08
We're Hopeful That Passage Bio (NASDAQ:PASG) Will Use Its Cash Wisely

Do Institutions Own Passage Bio, Inc. (NASDAQ:PASG) Shares?

Feb 01
Do Institutions Own Passage Bio, Inc. (NASDAQ:PASG) Shares?

Passage Bio on go with PBGM01 gene therapy trial in the U.S.

Jan 04

Need To Know: Passage Bio, Inc. (NASDAQ:PASG) Insiders Have Been Buying Shares

Dec 28
Need To Know: Passage Bio, Inc. (NASDAQ:PASG) Insiders Have Been Buying Shares

U.K. authorizes Passage Bio's PBGM01 trial

Dec 10

Passage Bio (PASG) Investor Presentation - Slideshow

Nov 16

Passage Bio EPS beats by $0.13

Nov 10

Passage Bio’s PBKR03 nabs Orphan drug tag and accelerated review status for Krabbe disease

Oct 28

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( $87.2M ) PASG } overtreffen de korte termijn passiva ( $17.0M ).

Langlopende schulden: De kortetermijnactiva PASG ( $87.2M ) overtreffen de langetermijnschulden ( $22.1M ).


Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: PASG is schuldenvrij.

Schuld verminderen: PASG heeft de afgelopen 5 jaar geen schulden gehad.


Balans


Analyse van de cashflow

Voor bedrijven die in het verleden gemiddeld verliesgevend zijn geweest, beoordelen we of ze ten minste 1 jaar kasstroom hebben.

Stabiele cash runway: PASG heeft op basis van de huidige vrije kasstroom voldoende kasstroom voor meer dan een jaar.

Voorspelling contante baan: PASG heeft voldoende kasruimte voor 1.1 jaar als de vrije kasstroom blijft dalen met een historisch percentage van 8 % per jaar.


Ontdek gezonde bedrijven